⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNRX News
VolitionRX Limited Common Stock
Volition Advances Nu.Q® NETs Platform Towards Commercialization
prnewswire.com
VNRX
Form 8-K
sec.gov
VNRX
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
prnewswire.com
VNRX
Form 8-K
sec.gov
VNRX
VolitionRx Announces Collaboration with Sysmex
prnewswire.com
VNRX
Form 8-K
sec.gov
VNRX
VolitionRx Announces Pricing of $4.6 Million Public Offering
prnewswire.com
VNRX
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
prnewswire.com
VNRX
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
prnewswire.com
VNRX
Form 8-K
sec.gov
VNRX